SARS-COV-2 ANTIVIc

National Institutes of Health

INTRODUCTION

NIH SARS-COV-2 ANTIVIRAL THERAPEUTICS SUMMIT

P e en e :
Dr. Francis Collins (NIH)
Dr. Anthony Fauci (NIAID)
Dr. Christopher Austin (NCATS)

OVERVIEW OF THE VIRUS AND THERAPEUTICS APPROACHES

S eake :
Dr. Mark Denison, Vanderbilt University

SESSION 1

VIRAL REPLICATION MACHINERY

Mode a o :
Dr. Tomas Cihlar, Gilead Sciences

Paneli :
Dr. Elizabeth Campbell, Rockefeller University
Dr. Matthias Götte, University of Alberta
Dr. George Painter, Emory University
Dr. Michael Sofia, Arbutus Biopharma, Inc.
Dr. Sandra Weller, University of Connecticut

VIRAL REPLICATION MACHINERY



				efficacy		

SESSION 2

PROTEASES (VIRAL AND HOST)

Mode a o :
Dr. Annaliesa Anderson, Pfizer

Paneli :
LTC Charlotte Lanteri, Walter Reed Army Institute of Research
Dr. Andrew Mesecar, Purdue University
Dr. Jennifer Nwankwo, 1910 Genetics
Dr. Celia Schiffer, University of Massachusetts Medical School

SESSION 3

EMERGING TARGETS, EMERGING MODALITIES

Mode a o :
Dr. Kara Carter, Evotec*
**C en aff lia ion: De oin The a e ic*

Paneli :
Dr. David Baker, University of Washington
Dr. Lillian Chiang, Evrys Bio, LLC
Dr. Matthew Disney, Scripps Research Institute
Dr. Kumar Saikatendu, Takeda Pharmaceuticals
Dr. Marla Weetall, PTC Therapeutics, Inc

SESSION 4

PRECLINICAL TOOLS

Mode a o :
Dr. Pei-Yong Shi, University of Texas Medical Branch

Paneli :
Dr. Sara Cherry, University of Pennsylvania
Dr. Emmie de Wit, NIAID/Rocky Mountain Laboratories, NIH
Dr. Jules O’Rear, [illegible]

S(sL T)er. 77.T 77.Te ge(of7(lbeene77.T)ed(s

SESSION 5

LESSONS FROM OTHER VIRUSES AND PREPARATION FOR THE FUTURE

Mode a o :
Dr. Daria Hazuda, Merck & Co.

Paneli :
Dr. Jay Bradner, Novartis
Dr. Courtney Fletcher, University of Nebraska Medical Center
Dr. Frederick Hayden, University of Virginia
Dr. Hilary Marston, NIAID

SUMMARY OF DISCUSSIONS AND PERSPECTIVES ON THE CHALLENGES AHEAD

S eake :
Dr. George Painter, Emory University
Dr. Richard Whitley, University of Alabama at Birmingham

SUMMARY AND PERSPECTIVE

RESOURCES

REFERENCES

(14)

R.

(15)

(16)

(17)

(21)

(22)

(23)

(24)

(25)

(26)

(27)

M.

(38)

(39)

(40)

(41)

(42)

(43)

(44)

(45)

(46)

(47)

'37(

- -

D%ÏÌ&ÓÕ×ÛÝßãåçëíïóõ÷ûýÿ1% Q ÈDæ,&p@MH @ I ˆy 9@M

(65)

(66) -